CAK复合体在雌激素受体阳性乳腺癌中的表达及其临床意义

doi:10.3760/cma.j.issn.1673-422X.2017.07.005

摘要/Abstract

摘要： 目的探究细胞周期蛋白依赖性激酶活化激酶（CAK）复合体各组分细胞周期蛋白依赖性激酶7（CDK7）、周期素H和辅助蛋白MAT1在雌激素受体阳性乳腺癌中的表达及其临床意义。方法选取在陕西省宝鸡市妇幼保健院乳腺科诊治的40例雌激素受体阳性乳腺癌患者，收集患者手术的乳腺癌组织和癌旁正常组织。实时荧光定量PCR（qRTPCR）检测组织中CDK7、周期素H、MAT1的表达情况，分析其与患者临床病理特征的相关性。结果 CDK7、周期素H和MAT1在肿瘤组织中的相对表达水平分别为2.54±0.78、2.21±0.56、2.46±0.58，在癌旁正常组织的相对表达水平分别为1.26±0.30、1.16±0.42、1.17±0.39，差异均有统计学意义（t=9.654，P<0.001；t=9.433，P<0.001；t=11.741，P<0.001）；周期素H和MAT1表达水平越高，临床分期越低，具有明显的相关性（U=3.17，P=0.01；U=2.53，P=0.01）；此外，MAT1水平高的患者肿瘤偏小（χ2=14.16，P=0.01）。结论 CAK复合体CDK7、周期素H和MAT1在雌激素受体阳性乳腺癌患者肿瘤组织中高表达，周期素H和MAT1与临床分期密切相关，且MAT1与患者肿瘤大小也具有明显相关性。

关键词: 乳腺肿瘤, 诊断, CAK复合体

Abstract: Objective To evaluate the expression and clinical significance of cyclin dependent kinase (CDK)activating kinase (CAK) complex including CDK7, cyclin H and accessory protein menage a trios 1 (MAT1) in estrogen receptorpositive breast cancer. MethodsA total of 40 patients with estrogen receptorpositive breast cancer from Department of Galactophore, Baoji Maternal and Child Care Service Centre of Shaanxi Province were investigated in this study. Breast cancer tissues and adjacent normal tissues were obtained from patients undergoing surgery. The mRNA expressions of CDK7, cyclin H and MAT1 in two types of tissues were measured by realtime fluorescent quantitative (qRT)PCR, and their correlations with clinicopathologic features of patients were analyzed. ResultsThe expressions of CDK7, cyclin H and MAT1 in cancer tissues were 2.54±0.78, 2.21±0.56 and 2.46±0.58, while those in adjacent normal tissues were 1.26±0.30, 1.16±0.42 and 1.17±0.39, and there were significantly differences between different types of tissues (t=9.654, P<0.001; t=9.433, P<0.001; t=11.741, P<0.001). The higher expressions of cyclin H and MAT1 in patients′ cancer tissues had the lower clinical stage, with significant correlations (U=3.17, P=0.01; U=2.53, P=0.01). In addition, the tumors were smaller in patients with higher expression levels of MAT1 (χ2=14.16, P=0.01). ConclusionThe expressions of CAK complex CDK7, cyclin H and MAT1 are elevated in estrogen receptorpositive breast cancer patients. Cyclin H and MAT1 are closely associated with clinical grade, and MAT1 is also significantly associated with tumor size.

Key words: Breast neoplasms, Diagnosis, CAK complex

李丹，胡海峰，夏秀林. CAK复合体在雌激素受体阳性乳腺癌中的表达及其临床意义[J]. 国际肿瘤学杂志, 2017, 44(7): 500-503.

Li Dan, Hu Haifeng, Xia Xiulin. Expression and clinical significance of CAK complex in estrogen receptorpositive breast cancer[J]. Journal of International Oncology, 2017, 44(7): 500-503.

参考文献

［1］ Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm［J］. Nat Rev Cancer, 2009, 9(3): 153-166. DOI: 10.1038/nrc2602. ［2］ Banyai G, Badi F, Coudreuse D, et al. Cdk1 activity acts as a quantitative platform for coordinating cell cycle progression with periodic transcription［J］. Nat Commun, 2016, 7: 11161. DOI: 10.1038/ncomms11161. ［3］ Su J, Zhou H, Tao Y, et al. HCdc14A is involved in cell cycle regulation of human brain vascular endothelial cells following injury induced by high glucose, free fatty acids and hypoxia［J］. Cell Signal, 2015, 27(1): 47-60. DOI: 10.1016/j.cellsig.2014.10.003. ［4］ Risal S, Adhikari D, Liu K. Animal models for studying the in vivo functions of cell cycle CDKs［J］. Methods Mol Biol, 2016, 1336: 155-166. DOI: 10.1007/978-1-4939-2926-9_13. ［5］ Wang Q, Li M, Zhang X, et al. Upregulation of CDK7 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis［J］. Exp Mol Pathol, 2016, 100(3): 514-521. DOI: 10.1016/j.yexmp.2016.05.001. ［6］ Schwartz BE, Larochelle S, Suter B, et al. Cdk7 is required for full activation of Drosophila heat shock genes and RNA polymerase Ⅱ phosphorylation in vivo［J］. Mol Cell Biol, 2003, 23(19): 6876-6886. ［7］冀全博, 徐小洁, 张强, 等. 人细胞周期蛋白H基因的真核表达载体构建和表达及功能检测［J］. 细胞与分子免疫学杂志, 2014, 30(9): 941-943. DOI: 10.13423/j.cnki.cjcmi.007091. ［8］ Pitts TM, Davis SL, Eckhardt SG, et al. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors［J］. Pharmacol Ther, 2014, 142(2): 258-269. DOI: 10.1016/j.pharmthera.2013.12.010. ［9］ Ali S, Heathcote DA, Kroll SH, et al. The development of a selective cyclindependent kinase inhibitor that shows antitumor activity［J］. Cancer Res, 2009, 69(15): 6208-6215. DOI: 10.1158/00085472.CAN090301. ［10］ Kwiatkowski N, Zhang T, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor［J］. Nature, 2014, 511(7511): 616-620. DOI: 10.1038/nature13393. ［11］陈万青, 郑荣寿. 中国女性乳腺癌发病死亡和生存状况［J］. 中国肿瘤临床, 2015, 42(13): 668674. DOI: 10.3969/j.issn.10008179.20150571. ［12］龚巍巍, 罗胜兰, 胡如英, 等. 2005—2010年浙江省女性乳腺癌、宫颈癌与卵巢癌生存率分析［J］. 中华预防医学杂志, 2014, 48(5): 366-369. DOI: 10.3760/cma.j.issn.02539624.2014.05.007. ［13］ LaubySecretan B, Scoccianti C, Loomis D, et al. 国际癌症研究机构工作组乳腺癌筛查简报［J］. 中国全科医学, 2015, 18(27): 3265-3267. ［14］谢杨, 周雪妍, 郝海平, 等. 核受体FXR代谢调控作用及肿瘤细胞增殖机制研究进展［J］. 生理学报, 2014, 66(2): 252-258. DOI: 10.13294/j.aps.2014.0030. ［15］ Ganuza M, Santamaría D. Cdk7: open questions beyond the prevailing model［J］. Cell Cycle, 2012, 11(19): 3519-3520. DOI: 10.4161/cc.21888. ［16］ Liang YC, Tsai SH, Chen L, et al. Resveratrolinduced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells［J］. Biochem Pharmacol, 2003, 65(7): 1053-1060. ［17］ Zhang S, Liu JP, Xu FQ, et al. Gene silencing of MAT1 mediated by siRNA inhibits cell proliferation and invasion in pancreatic cancer in vitro［J］. ChinGer J Clin Oncol, 2008, 7(5): 280-282. DOI: 10.1007/s10330-008-0020-4.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[3]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[4]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[5]	陈琦, 徐晨阳, 王寅, 雷大鹏. 高光谱成像在头颈部肿瘤诊疗中的应用现状[J]. 国际肿瘤学杂志, 2024, 51(5): 298-302.
[6]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[7]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[8]	张丽丽, 谭茹, 房雪利, 杨宇, 桑铮, 李宝生. 乳腺导管原位癌影像学诊断、病理学升级及影像学技术进展[J]. 国际肿瘤学杂志, 2024, 51(3): 166-169.
[9]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[10]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[11]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[12]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[13]	黄镇, 陈永顺. 循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.
[14]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[15]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.